M107 is the first potential disease-modifying drug candidate for the treatment of gastroparesis, a chronic and serious gastrointestinal disease affecting stomach nerves and muscles resulting in stomach paralysis and delayed stomach emptying. M107 seeks to treat the underlying pathology of gastroparesis by switching human pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages. M107 lowers inflammation in the stomach and increases the population of the interstitial cells of Cajal (i.e., the pacemaker cells of the stomach), allowing for increased stomach emptying and function and decreased fibrosis of the stomach pylorus.

M102 is a potential disease-modifying drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s disease. ALS is a fatal, progressive neurodegenerative disease affecting voluntary muscles. ALS is also a complex disease with multiple disease pathomechanisms. M102 takes a broad mechanistic approach to treat ALS with dual activation of NRF2 and HSF1 pathways affecting multiple ALS pathomechanisms including oxidative stress, neuro-inflammation, mitochondrial dysfunction, and protein misfolding. We are also developing patient stratification approaches for sporadic ALS patients that may allow for improved clinical outcomes.